国际肿瘤学杂志››2016,Vol. 43››Issue (1): 56-59.doi:10.3760/cma.j.issn.1673-422X.2016.01.016
邱旺旺,杨治力,郑起
收稿日期:
2015-04-02出版日期:
2016-01-08发布日期:
2015-12-03通讯作者:
郑起 E-mail:drqww1225@126.com基金资助:
国家自然科学基金(81272935)
Qiu Wangwang, Yang Zhili, Zheng Qi
Received:
2015-04-02Online:
2016-01-08Published:
2015-12-03Contact:
Zheng Qi E-mail:drqww1225@126.comSupported by:
National Natural Science Foundation of China (81272935)
摘要:环指蛋白43(RNF43)是一种重要的泛素链接酶。作为Wnt信号通路中的拮抗蛋白,RNF43具有重要的抗肿瘤作用。RNF43突变后会引起Wnt信号通路的异常激活,进而促进细胞的侵袭、转移与增殖。除此之外,在临床抗肿瘤的研究中发现,RNF43与Wnt通路相互作用的位点有望作为肿瘤治疗的分子靶标。近年来,随着相关研究的逐渐深入,RNF43的分子结构及其与Wnt通路中相关蛋白的作用机制已经逐渐明确。而在临床研究中,RNF43蛋白的类似物及相关疫苗也显示出RNF43在肿瘤治疗中的重要地位。
邱旺旺,杨治力,郑起. 环指蛋白43基因及其在消化系统肿瘤中的功能[J]. 国际肿瘤学杂志, 2016, 43(1): 56-59.
Qiu Wangwang, Yang Zhili, Zheng Qi. Ring finger protein 43 gene and its function in digestive system cancer[J]. Journal of International Oncology, 2016, 43(1): 56-59.
[1] Vilella AJ, Severin J, UretaVidal A, et al. EnsemblCompara gene trees: complete, duplicationaware phylogenetic trees in vertebrates[J]. Genome Res, 2009, 19(2): 327-335. DOI:10.1101/gr.073585.107. [2] Zebisch M, Xu Y, Krastev C, et al. Structural and molecular basis of ZNRF3/RNF43 transmembrane ubiquitin ligase inhibition by the Wnt agonist Rspondin[J]. Nat Commun, 2013, 4(16): 458464. DOI:10.1038/ncomms3787. [3] De Lau WB, Snel B, Clevers HC. The Rspondin protein family[J]. Genome Biol, 2012, 13(3): 242. DOI:10.1186/gb-2012-13-3-242. [4] Clevers H, Nusse R. Wnt/βCatenin signaling and disease[J]. Cell, 2012, 149(6): 1192-1205. DOI:10.1016/j.cell.2012.05.012. [5] Hao HX, Xie Y, Zhang Y, et al. ZNRF3 promotes Wnt receptor turnover in an Rspondinsensitive manner[J]. Nature, 2012, 485(7397): 195200. DOI:10.1038/nature11019. [6] Koo BK, Spit M, Jordens I, et al. Tumour suppressor RNF43 is a stemcell E3 ligase that induces endocytosis of Wnt receptors[J]. Nature, 2012, 488(7413): 665-669. DOI:10.1038/nature11308. [7] Moffat LL, Robinson RE, Bakoulis AA. The conserved transmembrane RING finger protein PLR1 downregulates Wnt signaling by reducing Frizzled, Ror and Ryk cellsurface levels in Celegans[J]. Development, 2014, 141(3): 617-628. DOI:10.1242/dev.101600. [8] Moad H, Pioszak AA. Reconstitution of Rspondin: LGR4: ZNRF3 adult stem cell growth factor signaling complexes with recombinant proteins produced in Escherichia coli[J]. Biochemistry, 2013, 52(41): 72957304. DOI:10.1021/bi401090h. [9] Chen PH, Chen XY, Lin ZH, et al. The structural basis of Rspondin recognition by LGR5 and RNF43[J]. Genes Dev, 2013, 27(12): 1345-1350. DOI:10.1101/gad.219915.113. [10] Peng WC, de Lau W, Madoori PK, et al. Structures of Wntantagonist ZNRF3 and its complex with Rspondin 1 and implications for signaling[J]. PLoS One, 2013, 8(12): e83110. DOI:10.1371/journal.pone.0083110. [11] Xie Y, Zamponi R, Charlat O, et al. Interaction with both ZNRF3 and LGR4 is required for the signalling activity of R-spondin[J]. EMBO Rep, 2013, 14(12): 1120-1126. DOI:10.1038/embor.2013.167. [12] Takahashi N, Yamaguchi K, Ikenoue T, et al. Identification of two Wntresponsive elements in the intron of RING finger protein 43 (RNF43) gene[J]. PLoS One, 2014, 9(1): e86582. DOI:10.1371/journal.pone.0086582. [13] Krausova M, Korinek V. Wnt signaling in adult intestinal stem cells and cancer[J]. Cell Signal, 2014, 26(3): 570-579. DOI:10.1016/j.cellsig.2013.11.032. [14] Shinada K, Tsukiyama T, Sho T, et al. RNF43 interacts with NEDL1 and regulates p53mediated transcription[J]. Biochem Biophys Res Commun, 2011, 404(1): 143-147. DOI:10.1016/j.bbrc.2010.11.082. [15] Giannakis M, Hodis E, Jasmine Mu X, et al. RNF43 is frequently mutated in colorectal and endometrial cancers[J]. Nat Genet, 2014, 46(12): 1264-1266. DOI:10.1038/ng.3127. [16] Wang K, Yuen ST, Xu J, et al. Wholegenome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer[J]. Nat Genet, 2014, 46(6): 573-582. DOI:10.1038/ng.2983. [17] Okuno K, Sugiura F, Hidai JI, et al. Phase Ⅰ clinical trial of a novel peptide vaccine in combination with UFT/LV for metastatic colorectal cancer[J]. Exp Ther Med, 2011, 2(1): 73-79. DOI:10.3892/etm.2010.182. [18] Inoue K, Sugiura F, Kogita A, et al. Clinical trial of a sevenpeptide vaccine and tegafururacil/leucovorin as combination therapy for advanced colorectal cancer[J]. Gan To Kagaku Ryoho, 2014, 41(10): 12761279. [19] Sugiura F, Inoue K, Kogita A, et al. Treatment outcome of peptide vaccination for advanced colorectal cancer[J]. Gan To Kagaku Ryoho, 2013, 40(12): 1584-1586. [20] Matsushita N, Aruga A, Inoue Y, et al. Phase Ⅰ clinical trial of a peptide vaccine combined with tegafururacil plus leucovorin for treatment of advanced or recurrent colorectal cancer[J]. Oncol Rep, 2013, 29(3): 951-959. DOI:10.3892/or.2013.2231. [21] Hijikata Y, MurahashiIga M, Okazaki T, et al. Development of novel immune therapies for solid tumors: phase Ⅰ clinical trials in a single institute[J]. Rinsho Ketsueki, 2012, 53(5): 487-492. [22] Wu J, Jiao Y, Dal Molin M, et al. Wholeexome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitindependent pathways[J]. Proc Natl Acad Sci USA, 2011, 108(52): 21188-21193. DOI:10.1073/pnas.1118046108. [23] Sakamoto H, Kuboki Y, Hatori T, et al. Clinicopathological significance of somatic RNF43 mutation and aberrant expression of ring finger protein 43 in intraductal papillary mucinous neoplasms of the pancreas[J]. Mod Pathol, 2015, 28(2): 261-267. DOI:10.1038/modpathol.2014.98. [24] Reid MD, Choi H, Balci S, et al. Serous cystic neoplasms of the pancreas: clinicopathologic and molecular characteristics[J]. Semin Diagn Pathol, 2014, 31(6): 475-483. DOI:10.1053/j.semdp.2014.08.009. [25] Gala MK, Mizukami Y, Le LP, et al. Germline mutations in oncogeneinduced senescence pathways are associated with multiple sessile serrated adenomas[J]. Gastroenterology, 2014, 146(2): 520529. DOI:10.1053/j.gastro.2013.10.045. [26] Xing C, Zhou W, Ding S, et al. Reversing effect of ring finger protein 43 inhibition on malignant phenotypes of human hepatocellular carcinoma[J]. Mol Cancer Ther, 2013, 12(1): 94-103. DOI:10.1158/1535-7163.MCT-12-0672. [27] Ong CK, Subimerb C, Pairojkul CA, et al. Exome sequencing of liver flukeassociated cholangiocarcinoma[J]. Nat Genet, 2012, 44(6): 690-1113. DOI:10.1038/ng.2273. [28] Jiang X, Hao HX, Growney JD, et al. Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma[J]. Proc Natl Acad Sci USA, 2013, 110(31): 12649-12654. DOI:10.1073/pnas.1307218110. |
[1] | 吴旻杭, 孙文政, 于庆卓, 郭蓉, 叶辉, 杜莹, 邱晋, 安华章, 曹莉莉.RNF43通过β-catenin抑制黑色素瘤细胞PD-L1表达并促进CD8+T细胞介导的抗肿瘤免疫反应[J]. 国际肿瘤学杂志, 2023, 50(7): 407-412. |
[2] | 吴佳丽, 张佳慧, 张萍, 肖昕悦, 李睿, 张红宇.Bcl-2 BH4选择性抑制剂BDA-366抑制NK/T细胞淋巴瘤细胞的机制研究[J]. 国际肿瘤学杂志, 2023, 50(7): 413-418. |
[3] | 李彬, 张桂芳, 周林静, 杨小冬, 何秋立, 贾思思, 黄普超, 梁嘉欣.三阴性乳腺癌中PIK3CA基因状态与临床特征及预后的关系[J]. 国际肿瘤学杂志, 2023, 50(5): 263-267. |
[4] | 刘博翰, 黄俊星.溶质载体SLC7A5及SLC7A11基因在恶性肿瘤中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(5): 280-284. |
[5] | 刘玉杰, 赵志强, 王子琤.早期结直肠癌患者外周血单个核细胞中TOP2A、ERBB2的水平及其诊断价值[J]. 国际肿瘤学杂志, 2023, 50(12): 717-722. |
[6] | 邓莉莉, 段星宇, 李保中.HER2靶向药物及其联合治疗方案在胃及食管胃结合部腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(12): 751-757. |
[7] | 陈群响, 张晓钰, 张妍, 张凯翔, 李捷, 陈曦.伊尼妥单抗联合长春瑞滨治疗HER2阳性转移性乳腺癌1例[J]. 国际肿瘤学杂志, 2023, 50(12): 763-765. |
[8] | 张子悦, 郑斯豪, 高彦君, 姚颐, 宋启斌.基于CRISPR/Cas9的基因编辑技术及其在肿瘤治疗中的应用[J]. 国际肿瘤学杂志, 2022, 49(9): 546-549. |
[9] | 黎立喜, 温霆宇, 管秀雯, 翟婧彤, 马飞.早发性乳腺癌的遗传易感基因及临床特征[J]. 国际肿瘤学杂志, 2022, 49(4): 206-209. |
[10] | 徐凯, 文刚, 李瑞, 田园.淋巴细胞与C反应蛋白比值对消化系统肿瘤预后价值的研究进展[J]. 国际肿瘤学杂志, 2022, 49(10): 627-629. |
[11] | 张静, 黄守国, 夏鹰.CeRNA网络介导恶性肿瘤表型调控的机制研究[J]. 国际肿瘤学杂志, 2021, 48(9): 544-548. |
[12] | 庄伟涛, 乔贵宾.基于表观遗传标志的液体活检在实体瘤诊疗中的研究与应用[J]. 国际肿瘤学杂志, 2021, 48(6): 358-361. |
[13] | 李甜甜, 石莉程, 孔辉, 齐栩.肺腺癌驱动基因与静脉血栓栓塞症相关性研究[J]. 国际肿瘤学杂志, 2021, 48(6): 370-373. |
[14] | 居欣月, 胡春梅, 赵月, 唐艳.CDX2与胃肠道肿瘤[J]. 国际肿瘤学杂志, 2021, 48(6): 374-376. |
[15] | 魏永健, 胡进静, 李汛.CDCA8与肿瘤发生发展及干细胞干性维持的关系[J]. 国际肿瘤学杂志, 2021, 48(4): 216-219. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||